Guggenheim Raises Price Target for Bruker Corporation (BRKR)
On January 26, Guggenheim analyst Subbu Nambi reiterated her Buy rating on Bruker Corporation (NASDAQ:BRKR).
Bruker Corp (BRKR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Sivik Global Healthcare Krishen Sud | 65,000 | $3,062 | +9% | 0.89% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $38.36 | 2,608 | $100,042.88 | 38,462,171 | 2025-06-06 | Filing | |
| $47.40 | 500 | $23,697.50 | 3,472 | 2025-03-10 | Filing | |
| $51.23 | 6,937 | $355,382.51 | 38,459,563 | 2025-02-18 | Filing | |
| $50.75 | 13,063 | $662,947.25 | 38,452,626 | 2025-02-18 | Filing | |
| $51.36 | 3,583 | $184,022.88 | 38,439,563 | 2024-11-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $49.20 | 2,000 | $98,400.00 | 128,443 | 2026-01-15 | Filing | |
| $55.00 | 7,000 | $385,000.00 | 128,443 | 2026-01-12 | Filing | |
| $49.25 | 15,337 | $755,347.25 | 128,443 | 2026-01-05 | Filing | |
| $50.00 | 14,000 | $700,000.00 | 143,780 | 2026-01-05 | Filing | |
| $50.00 | 4,506 | $225,300.00 | 157,780 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,259,824 | $483,340,309 | 0.01% | |
| 2. | 9,480,665 | $446,634,130 | 14.75% | |
| 3. | 1,640,715 | $77,294,083 | 0.76% | |
| 4. | 141,618 | $51,832,188 | 0.19% | |
| 5. | 1,000,467 | $47,132,001 | 0.01% |
News See All
12 Best Medical Devices Stocks According to Hedge Funds
It is challenging to identify segments within the markets that appear to be defensive plays, yet offer innovation potential.
Bruker Corporation (BRKR): A Bull Case Theory
We came across a bullish thesis on Bruker Corporation on r/valueinvesting by TheDynamicMolecule. In this article, we will summarize the bulls’ thesis on BRKR.
Goldman Sachs Initiates Sell Rating On Bruker Corporation (BRKR)
According to The Fly, on December 9, 2025, Goldman Sachs started Bruker Corporation (NASDAQ:BRKR) with a Sell rating and a $40 price objective.
13 Best Nanotechnology Stocks to Buy Now
Nanotechnology is defined by the National Nanotechnology Initiative as the control of matter in the range of 1 to 100 nanometers, where materials have characteristics distinct from those of bulk forms...
BBH Select Series - Mid Cap Fund Sold Bruker Corporation (BRKR) Due to Policy Uncertainty
Brown Brothers Harriman, an investment management company, released its Q3 2025 investor letter for the BBH Select Series - Mid Cap Fund. A copy of the same can be downloaded here.
London Company Large Cap Sold Its Holdings in Bruker Corporation (BRKR) in Q3
The London Company, an investment management company, released “The London Company Large Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Bruker Corporation (NASDAQ:BRKR) Q3 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Bruker Corporation Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Bruker (BRKR) Secures New Orders for High-Performance NMR Instruments Across Top U.S. Research Centers
Bruker Corporation (NASDAQ:BRKR) ranks among the best medical device stocks to invest in.
12 Best Medical Device Stocks to Invest In Now
As chronic diseases like diabetes and cancer become more common, medical device technology is becoming increasingly innovative.